Figure 1 Treat to target, remission and low disease activity in SLE

Slides:

Advertisements

Similar presentations

The Patient Experience With Systemic Lupus Erythematosus

Advertisements

Systemic Lupus Erythematosus

Figure 3 The induction of anti-DNA antibodies by bacterial DNA

Figure 1 Lymphocytes during the disease

of different experimental arthritis models

Figure 3 Connexins in cartilage

Figure 5 Involvement of B cells in SLE

Figure 4 The theoretical contribution of genetic and

Figure 1 Historical evolution of the clinical classification and

Figure 2 A timeline summarizing the development of diagnostic tools in rheumatology Figure 2 | A timeline summarizing the development of diagnostic tools.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Heat map of targeted therapies in autoimmune diseases

Figure 1 Organs involved in coeliac-disease-associated autoimmunity

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Schematic comparison of expected

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 3 Nucleic acid sensors in SLE

Nat. Rev. Rheumatol. doi: /nrrheum

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Supplementary Figure 1. Longitudinal study in a representative number of SLE patients one year before (t1), at the time (t2), and one year after renal.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Approaches to targeting inhibitory immune receptors

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Overview of biosimilar product development

Nat. Rev. Nephrol. doi: /nrneph

Management of Systemic Lupus Erythematosus

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 The current model of the pathogenesis of SLE

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 Principles for the diagnosis and management of osteoarthritis

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Chronic inflammation and DNA damage in people with SLE

Figure 3 Nuclear-penetrating autoantibodies and synthetic lethality

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 2 Cellular contributions to the development of SLE

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Figure 2 Phenotypes of osteoarthritis

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Figure 1 Differential effects of bone-forming agents on bone surfaces

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Figure 2 The main effects of adipokines on bone remodelling in osteoarthritis Figure 2 | The main effects of adipokines on bone remodelling in osteoarthritis.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Celiac disease as a model for SLE

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Presentation transcript:

Figure 1 Treat to target, remission and low disease activity in SLE Figure 1 | Treat to target, remission and low disease activity in SLE. Control of active disease in systemic lupus erythematosus (SLE) can be conceived as concentric circles of progressively improving treatment response states associated with stepwise improvements in outcome, representing a continuum along which treatment can be directed. Rates of damage accrual will be lower at each stage of disease control, theoretically reaching zero for complete off-treatment remission. LLDAS, lupus low disease activity state. Morand, E. F. (2016) Remission in SLE — are we there yet? Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.174